Loading clinical trials...
Loading clinical trials...
This will be a hospital-based retrospective multi-center study on epidemiologic and clinical characteristics of optic neuritis among Chinese. The investigation will cover about 29 provinces or municipalities all around China.
This national investigation will be conducted to describe the epidemiology and clinical characteristics of optic neuritis in China. All the patients will be divided into 3 groups according to the serum demyelinating antibodies (Aquaporin-4 antibody seropositive group, Myelin oligodendrocyte glycoprotein antibody seropositive group and double seronegative group). The investigator will analyze the differences among the three groups. Primary outcomes: * To dig out the different visual acuity (VA, LogMAR) prognosis among the three groups; * To calculate the annual relapse rate (ARR) differences among the three groups (relapse times in all the follow-up time in each group/ follow-up time (years) in all in each group). Secondary outcomes: * Other epidemiological and clinical characteristics of optic neuritis patients will be analyzed among the three groups; * Orbital or Brain MRI is required in this study, which could avoid the misdiagnosis. We will collect and analyze these MRI data too (including the optic nerve lesions in T2 weight images and T1 enhanced MRI); * Results of optical coherence tomography (OCT) (including peripapillary retinal nerve fiber layer, macular thickness ,and ganglion cell and inner plexiform layer complex) at different time point are also needed in this study. However, OCT is not necessarily required; * Visual fields at different time points are also encouraged to provide if they are available.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Start Date
May 1, 2020
Primary Completion Date
December 3, 2020
Completion Date
June 30, 2021
Last Updated
January 20, 2021
1,000
ESTIMATED participants
observation
OTHER
Lead Sponsor
Chinese PLA General Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03401879